Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 313

1.

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.

Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O'Shea JJ.

J Leukoc Biol. 2018 Sep;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R. Epub 2018 Jul 12. Review.

PMID:
29999544
2.

Non-classical monocytes as mediators of tissue destruction in arthritis.

Puchner A, Saferding V, Bonelli M, Mikami Y, Hofmann M, Brunner JS, Caldera M, Goncalves-Alves E, Binder NB, Fischer A, Simader E, Steiner CW, Leiss H, Hayer S, Niederreiter B, Karonitsch T, Koenders MI, Podesser BK, O'Shea JJ, Menche J, Smolen JS, Redlich K, Blüml S.

Ann Rheum Dis. 2018 Oct;77(10):1490-1497. doi: 10.1136/annrheumdis-2018-213250. Epub 2018 Jun 29.

3.

NCR+ ILC3 maintain larger STAT4 reservoir via T-BET to regulate type 1 features upon IL-23 stimulation in mice.

Mikami Y, Scarno G, Zitti B, Shih HY, Kanno Y, Santoni A, O'Shea JJ, Sciumè G.

Eur J Immunol. 2018 Jul;48(7):1174-1180. doi: 10.1002/eji.201847480. Epub 2018 Apr 16.

PMID:
29524223
4.

Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair.

Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, Sen SK, Shaik J, Smelkinson M, Tamoutounour S, Collins N, Bouladoux N, Dzutsev A, Rosshart SP, Arbuckle JH, Wang CR, Kristie TM, Rehermann B, Trinchieri G, Brenchley JM, O'Shea JJ, Belkaid Y.

Cell. 2018 Feb 8;172(4):784-796.e18. doi: 10.1016/j.cell.2017.12.033. Epub 2018 Jan 18.

PMID:
29358051
5.

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ.

Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267.

6.

Epigenomic Views of Innate Lymphoid Cells.

Sciumè G, Shih HY, Mikami Y, O'Shea JJ.

Front Immunol. 2017 Nov 13;8:1579. doi: 10.3389/fimmu.2017.01579. eCollection 2017. Review.

7.

IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion.

Le Saout C, Luckey MA, Villarino AV, Smith M, Hasley RB, Myers TG, Imamichi H, Park JH, O'Shea JJ, Lane HC, Catalfamo M.

JCI Insight. 2017 Nov 16;2(22). pii: 96228. doi: 10.1172/jci.insight.96228. [Epub ahead of print]

8.

STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells.

Majri SS, Fritz JM, Villarino AV, Zheng L, Kanellopoulou C, Chaigne-Delalande B, Grönholm J, Niemela JE, Afzali B, Biancalana M, Pittaluga S, Sun A, Cohen JL, Holland SM, O'Shea JJ, Uzel G, Lenardo MJ.

J Immunol. 2018 Jan 1;200(1):110-118. doi: 10.4049/jimmunol.1701133. Epub 2017 Nov 29.

9.

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ.

Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6. Review. Erratum in: Nat Rev Drug Discov. 2017 Dec 28;17 (1):78.

PMID:
29104284
10.

Group 1 Innate Lymphoid Cell Lineage Identity Is Determined by a cis-Regulatory Element Marked by a Long Non-coding RNA.

Mowel WK, McCright SJ, Kotzin JJ, Collet MA, Uyar A, Chen X, DeLaney A, Spencer SP, Virtue AT, Yang E, Villarino A, Kurachi M, Dunagin MC, Pritchard GH, Stein J, Hughes C, Fonseca-Pereira D, Veiga-Fernandes H, Raj A, Kambayashi T, Brodsky IE, O'Shea JJ, Wherry EJ, Goff LA, Rinn JL, Williams A, Flavell RA, Henao-Mejia J.

Immunity. 2017 Sep 19;47(3):435-449.e8. doi: 10.1016/j.immuni.2017.08.012.

11.

Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells.

Villarino AV, Sciumè G, Davis FP, Iwata S, Zitti B, Robinson GW, Hennighausen L, Kanno Y, O'Shea JJ.

J Exp Med. 2017 Oct 2;214(10):2999-3014. doi: 10.1084/jem.20150907. Epub 2017 Sep 15.

12.

IL-10 induces a STAT3-dependent autoregulatory loop in TH2 cells that promotes Blimp-1 restriction of cell expansion via antagonism of STAT5 target genes.

Poholek AC, Jankovic D, Villarino AV, Petermann F, Hettinga A, Shouval DS, Snapper SB, Kaech SM, Brooks SR, Vahedi G, Sher A, Kanno Y, O'Shea JJ.

Sci Immunol. 2016 Oct;1(5). pii: eaaf8612. Epub 2016 Nov 11.

13.

The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells.

Iwata S, Mikami Y, Sun HW, Brooks SR, Jankovic D, Hirahara K, Onodera A, Shih HY, Kawabe T, Jiang K, Nakayama T, Sher A, O'Shea JJ, Davis FP, Kanno Y.

Immunity. 2017 Jun 20;46(6):983-991.e4. doi: 10.1016/j.immuni.2017.05.005. Epub 2017 Jun 13.

14.

BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency.

Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, Kamenyeva O, Keith J, Sayed A, Kasperaviciute D, Mueller M, Hughes JD, Fuss IJ, Sadiyah MF, Montgomery-Recht K, McElwee J, Restifo NP, Strober W, Linterman MA, Wingfield PT, Uhlig HH, Roychoudhuri R, Aitman TJ, Kelleher P, Lenardo MJ, O'Shea JJ, Cooper N, Laurence ADJ.

Nat Immunol. 2017 Jul;18(7):813-823. doi: 10.1038/ni.3753. Epub 2017 May 22.

15.

Extraordinary effects of unnatural pairings.

Villarino A, O'Shea JJ.

Elife. 2017 May 12;6. pii: e27198. doi: 10.7554/eLife.27198.

16.

Mechanisms and consequences of Jak-STAT signaling in the immune system.

Villarino AV, Kanno Y, O'Shea JJ.

Nat Immunol. 2017 Mar 22;18(4):374-384. doi: 10.1038/ni.3691. Review.

PMID:
28323260
17.

Targeting cytokine signaling in autoimmunity: back to the future and beyond.

Hirahara K, Schwartz D, Gadina M, Kanno Y, O'Shea JJ.

Curr Opin Immunol. 2016 Dec;43:89-97. doi: 10.1016/j.coi.2016.10.001. Epub 2016 Nov 4. Review.

PMID:
27821272
18.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O'Shea JJ, Kaplan MJ, Gadina M.

Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818.

19.

BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers.

Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, Fabozzi G, Shih HY, Kanno Y, Muto A, Zhu J, Gattinoni L, O'Shea JJ, Okkenhaug K, Igarashi K, Leonard WJ, Restifo NP.

Nat Immunol. 2016 Jul;17(7):851-860. doi: 10.1038/ni.3441. Epub 2016 May 9.

20.

Developmental Acquisition of Regulomes Underlies Innate Lymphoid Cell Functionality.

Shih HY, Sciumè G, Mikami Y, Guo L, Sun HW, Brooks SR, Urban JF Jr, Davis FP, Kanno Y, O'Shea JJ.

Cell. 2016 May 19;165(5):1120-1133. doi: 10.1016/j.cell.2016.04.029. Epub 2016 May 5.

21.

Signal transducer and activator of transcription 5 (STAT5) paralog dose governs T cell effector and regulatory functions.

Villarino A, Laurence A, Robinson GW, Bonelli M, Dema B, Afzali B, Shih HY, Sun HW, Brooks SR, Hennighausen L, Kanno Y, O'Shea JJ.

Elife. 2016 Mar 21;5. pii: e08384. doi: 10.7554/eLife.08384.

22.

The Histone Variant MacroH2A1.2 Is Necessary for the Activation of Muscle Enhancers and Recruitment of the Transcription Factor Pbx1.

Dell'Orso S, Wang AH, Shih HY, Saso K, Berghella L, Gutierrez-Cruz G, Ladurner AG, O'Shea JJ, Sartorelli V, Zare H.

Cell Rep. 2016 Feb 9;14(5):1156-1168. doi: 10.1016/j.celrep.2015.12.103. Epub 2016 Jan 28.

23.

Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells.

Jain R, Chen Y, Kanno Y, Joyce-Shaikh B, Vahedi G, Hirahara K, Blumenschein WM, Sukumar S, Haines CJ, Sadekova S, McClanahan TK, McGeachy MJ, O'Shea JJ, Cua DJ.

Immunity. 2016 Jan 19;44(1):131-142. doi: 10.1016/j.immuni.2015.11.009. Epub 2015 Dec 29.

24.

A Metabolic Switch for Th17 Pathogenicity.

Davis FP, Kanno Y, O'Shea JJ.

Cell. 2015 Dec 3;163(6):1308-10. doi: 10.1016/j.cell.2015.11.033.

25.

Correction: The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell-Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9-Producing T Cells.

Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, Cruz AC, Penumetcha P, Hayes ET, Pelletier M, Gabay O, Walsh M, Ferdinand JR, Keane-Myers A, Choi Y, O'Shea JJ, Al-Shamkhani A, Kaplan MH, Gery I, Siegel RM, Meylan F.

J Immunol. 2015 Dec 15;195(12):5839-40. doi: 10.4049/jimmunol.1502026. No abstract available.

26.

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

Schwartz DM, Bonelli M, Gadina M, O'Shea JJ.

Nat Rev Rheumatol. 2016 Jan;12(1):25-36. doi: 10.1038/nrrheum.2015.167. Epub 2015 Dec 3. Review.

27.

IL-27 shakes up the establishment of ectopic lymphoid structures.

Villarino AV, O'Shea JJ, Hunter CA.

J Exp Med. 2015 Oct 19;212(11):1757. doi: 10.1084/jem.21211insight4. No abstract available.

28.

Decernotinib: A Next-Generation Jakinib.

Gadina M, Schwartz DM, O'Shea JJ.

Arthritis Rheumatol. 2016 Jan;68(1):31-4. doi: 10.1002/art.39463. No abstract available.

29.

An autoregulatory enhancer controls mammary-specific STAT5 functions.

Metser G, Shin HY, Wang C, Yoo KH, Oh S, Villarino AV, O'Shea JJ, Kang K, Hennighausen L.

Nucleic Acids Res. 2016 Feb 18;44(3):1052-63. doi: 10.1093/nar/gkv999. Epub 2015 Oct 7.

30.

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.

Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5. doi: 10.1073/pnas.1516208112. Epub 2015 Sep 22.

31.

Super-enhancers: Asset management in immune cell genomes.

Witte S, O'Shea JJ, Vahedi G.

Trends Immunol. 2015 Sep;36(9):519-26. doi: 10.1016/j.it.2015.07.005. Epub 2015 Aug 12. Review.

32.

EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion.

Yang XP, Jiang K, Hirahara K, Vahedi G, Afzali B, Sciume G, Bonelli M, Sun HW, Jankovic D, Kanno Y, Sartorelli V, O'Shea JJ, Laurence A.

Sci Rep. 2015 Jun 19;5:10643. doi: 10.1038/srep10643.

33.

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.

Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, Restifo NP, O'Shea JJ, Medoff BD, Shamji AF, Schreiber SL, Sharpe AH, Shaw SY, Xavier RJ.

Elife. 2015 May 22;4. doi: 10.7554/eLife.05920.

34.

Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity.

Hirahara K, Onodera A, Villarino AV, Bonelli M, Sciumè G, Laurence A, Sun HW, Brooks SR, Vahedi G, Shih HY, Gutierrez-Cruz G, Iwata S, Suzuki R, Mikami Y, Okamoto Y, Nakayama T, Holland SM, Hunter CA, Kanno Y, O'Shea JJ.

Immunity. 2015 May 19;42(5):877-89. doi: 10.1016/j.immuni.2015.04.014.

35.

PAPST, a User Friendly and Powerful Java Platform for ChIP-Seq Peak Co-Localization Analysis and Beyond.

Bible PW, Kanno Y, Wei L, Brooks SR, O'Shea JJ, Morasso MI, Loganantharaj R, Sun HW.

PLoS One. 2015 May 13;10(5):e0127285. doi: 10.1371/journal.pone.0127285. eCollection 2015.

36.

The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.

Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, Cruz AC, Penumetcha P, Hayes ET, Pelletier M, Gabay O, Walsh M, Ferdinand JR, Keane-Myers A, Choi Y, O'Shea JJ, Al-Shamkhani A, Kaplan MH, Gery I, Siegel RM, Meylan F.

J Immunol. 2015 Apr 15;194(8):3567-82. doi: 10.4049/jimmunol.1401220. Epub 2015 Mar 18. Erratum in: J Immunol. 2015 Dec 15;195(12):5839-40.

37.

Super-enhancers delineate disease-associated regulatory nodes in T cells.

Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SC, Erdos MR, Davis SR, Roychoudhuri R, Restifo NP, Gadina M, Tang Z, Ruan Y, Collins FS, Sartorelli V, O'Shea JJ.

Nature. 2015 Apr 23;520(7548):558-62. doi: 10.1038/nature14154. Epub 2015 Feb 16.

38.

Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ.

Astry B, Venkatesha SH, Laurence A, Christensen-Quick A, Garzino-Demo A, Frieman MB, O'Shea JJ, Moudgil KD.

Clin Immunol. 2015 Apr;157(2):228-38. doi: 10.1016/j.clim.2015.01.011. Epub 2015 Feb 7.

39.

The JAK-STAT pathway: impact on human disease and therapeutic intervention.

O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A.

Annu Rev Med. 2015;66:311-28. doi: 10.1146/annurev-med-051113-024537. Review.

40.

Mechanisms of Jak/STAT signaling in immunity and disease.

Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ.

J Immunol. 2015 Jan 1;194(1):21-7. doi: 10.4049/jimmunol.1401867. Review.

41.

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones.

Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR, Vahedi G, Heightman TD, Garcia BA, Reinberg D, Siebenlist U, O'Shea JJ, Ozato K.

Nat Struct Mol Biol. 2014 Dec;21(12):1047-57. doi: 10.1038/nsmb.2912. Epub 2014 Nov 10.

42.

Proprotein convertase FURIN constrains Th2 differentiation and is critical for host resistance against Toxoplasma gondii.

Oksanen A, Aittomäki S, Jankovic D, Ortutay Z, Pulkkinen K, Hämäläinen S, Rokka A, Corthals GL, Watford WT, Junttila I, O'Shea JJ, Pesu M.

J Immunol. 2014 Dec 1;193(11):5470-9. doi: 10.4049/jimmunol.1401629. Epub 2014 Oct 29.

43.

An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome.

Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, DiMattia MA, Zaal KJ, Sanchez GA, Kim H, Chapelle D, Plass N, Huang Y, Villarino AV, Biancotto A, Fleisher TA, Duncan JA, O'Shea JJ, Benseler S, Grom A, Deng Z, Laxer RM, Goldbach-Mansky R.

Nat Genet. 2014 Oct;46(10):1140-6. doi: 10.1038/ng.3089. Epub 2014 Sep 14.

44.

Transcriptional and epigenetic networks of helper T and innate lymphoid cells.

Shih HY, Sciumè G, Poholek AC, Vahedi G, Hirahara K, Villarino AV, Bonelli M, Bosselut R, Kanno Y, Muljo SA, O'Shea JJ.

Immunol Rev. 2014 Sep;261(1):23-49. doi: 10.1111/imr.12208. Review.

45.

Enhancing the understanding of asthma.

Vahedi G, Richard AC, O'Shea JJ.

Nat Immunol. 2014 Aug;15(8):701-3. doi: 10.1038/ni.2946. No abstract available.

46.

Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response.

Tarrio ML, Lee SH, Fragoso MF, Sun HW, Kanno Y, O'Shea JJ, Biron CA.

J Immunol. 2014 Jul 1;193(1):354-63. doi: 10.4049/jimmunol.1302999. Epub 2014 Jun 6.

47.

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts.

Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ.

J Immunol. 2014 Jul 1;193(1):48-55. doi: 10.4049/jimmunol.1400063. Epub 2014 Jun 2.

48.

Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.

Bonelli M, Shih HY, Hirahara K, Singelton K, Laurence A, Poholek A, Hand T, Mikami Y, Vahedi G, Kanno Y, O'Shea JJ.

Curr Top Microbiol Immunol. 2014;381:279-326. doi: 10.1007/82_2014_371. Review.

49.

In search of magic bullets: the golden age of immunotherapeutics.

O'Shea JJ, Kanno Y, Chan AC.

Cell. 2014 Mar 27;157(1):227-40. doi: 10.1016/j.cell.2014.03.010. Review.

50.

A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3.

Steward-Tharp SM, Laurence A, Kanno Y, Kotlyar A, Villarino AV, Sciume G, Kuchen S, Resch W, Wohlfert EA, Jiang K, Hirahara K, Vahedi G, Sun HW, Feigenbaum L, Milner JD, Holland SM, Casellas R, Powrie F, O'Shea JJ.

Blood. 2014 May 8;123(19):2978-87. doi: 10.1182/blood-2013-09-523167. Epub 2014 Mar 14.

Supplemental Content

Loading ...
Support Center